What Catalysts Could Shift the Narrative for uniQure After Breakthrough AMT-130 Data? [Yahoo! Finance]
PTC Therapeutics, Inc. (PTCT)
Last ptc therapeutics, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ptcbio.com
Company Research
Source: Yahoo! Finance
discount rate ticked up marginally from 6.70% to 6.76%. This comes amid intensified analyst attention, prompted by encouraging three-year clinical data for the company's AMT-130 gene therapy in Huntington's disease. As investors consider both opportunities and emerging risks, stay tuned for guidance on how to track these pivotal developments moving forward. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value uniQure. What Wall Street Has Been Saying ?? Bullish Takeaways Cantor Fitzgerald increased its price target on uniQure significantly, from $47 to $80, maintaining its Overweight rating. Cantor highlighted strong three-year data for AMT-130 in Huntington's disease and elevated the probability of program success in the U.S. to 75% from 45%, and in Europe to 45% from 15%. RBC Capital raised its price target to $55 from $24, staying Outperform, crediting updated 36-month data for showing benefits consistent acr
Show less
Read more
Impact Snapshot
Event Time:
PTCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTCT alerts
High impacting PTC Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTCT
News
- Principal Spectrum Preferred Secs Active ETF declares monthly distribution of $0.0827 [Seeking Alpha]Seeking Alpha
- Principal Investment Grade Corporate Active ETF declares monthly distribution of $0.0792 [Seeking Alpha]Seeking Alpha
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- PTC Therapeutics (NASDAQ:PTCT) was downgraded by analysts at Royal Bank Of Canada from an "outperform" rating to a "sector perform" rating.MarketBeat
PTCT
Earnings
- 11/4/25 - Beat
PTCT
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form SCHEDULE
- 12/3/25 - Form 4
- PTCT's page on the SEC website